BCRX Stock: Price, Earnings History and SEC Filings
BioCryst Pharmaceuticals, Inc. (BCRX) last traded at $8.47, down 0.59% on the latest session and up 1.7% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $0.30 against an analyst estimate of $0.14, a beat of 114.3%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
BCRX earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 5, 2026 | $0.30 | $0.14 | +114.29% |
| Mar 2026 | May 6, 2026 | $-0.03 | $0.06 | -150.00% |
| Dec 2025 | Feb 26, 2026 | $1.12 | $0.07 | +1500.00% |
| Sep 2025 | Nov 3, 2025 | $0.06 | $0.07 | -14.29% |
BCRX beat the analyst EPS estimate in 2 of its last 4 reported quarters. Source: Nasdaq.
How BCRX reacts to earnings
Across its last 8 earnings releases, BCRX moved 7.6% on average the next session, in either direction. It rose after 4 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-05 | Before open | +0.55% |
| 2026-05-06 | Before open | -2.21% |
| 2026-02-26 | Before open | +4.64% |
| 2026-01-12 | After close | -4.80% |
| 2025-11-03 | Before open | -6.28% |
| 2025-10-14 | Before open | -8.81% |
| 2025-08-04 | Before open | +9.81% |
| 2025-05-05 | Before open | +23.52% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
BCRX financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $875M | $264M | – | 30.2% | $1.21 |
| 2024 | $451M | -$89M | – | -19.7% | $-0.43 |
| 2023 | $331M | -$227M | – | -68.4% | $-1.18 |
| 2022 | $271M | -$247M | – | -91.2% | $-1.33 |
| 2021 | $157M | -$184M | – | -117.1% | $-1.03 |
| 2020 | $18M | -$183M | – | -1026.4% | $-1.09 |
| 2019 | $49M | -$109M | -$90M | -223.0% | – |
| 2018 | $21M | -$101M | -$93M | -490.3% | – |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for BCRX
- 10-Q · Aug 5, 2026
- 8-K · Aug 5, 2026Results of operations, Regulation FD disclosure, Financial statements and exhibits
- 8-K · Jun 29, 2026Regulation FD disclosure, Financial statements and exhibits
- 8-K · Jun 12, 2026Officer or director change, Shareholder vote, Financial statements and exhibits
- 10-Q · May 6, 2026
- 8-K · May 6, 2026Results of operations, Regulation FD disclosure, Financial statements and exhibits
- 8-K · May 4, 2026Regulation FD disclosure, Financial statements and exhibits
- DEF 14A · Apr 23, 2026
- 10-K · Feb 26, 2026
- 8-K · Feb 26, 2026Results of operations, Regulation FD disclosure, Financial statements and exhibits
Insider filing activity
BCRX insiders filed 5 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
BCRX news
- How New HAE Data At BioCryst Pharmaceuticals Stock Has Changed Its Investment StoryOct 31, 2026 · finance.yahoo.com
- BioCryst stock: Wedbush trims valuation targetOct 30, 2026 · ad-hoc-news.de
- Wall Street Analysts See a 137.91% Upside in BioCryst (BCRX): Can the Stock Really Move This High?Oct 30, 2026 · finance.yahoo.com
- Pacira BioSciences (PCRX) Reports Next Week: Wall Street Expects Earnings GrowthOct 29, 2026 · finance.yahoo.com
- Is AxoGen (AXGN) Outperforming Other Medical Stocks This Year?Oct 29, 2026 · finance.yahoo.com
- BioCryst to Present New Data for ORLADEYO® (berotralstat) and Navenibart at the 2026 American College of Allergy, Asthma & Immunology Annual Scientific MeetingOct 29, 2026 · finance.yahoo.com
- BioCryst Pharmaceuticals (BCRX) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseOct 28, 2026 · finance.yahoo.com
- Wedbush cuts target for BioCryst stock from USD 20.00 to USD 18.00Oct 27, 2026 · ad-hoc-news.de
About BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc. (BCRX) is a US-listed public company on Nasdaq. The SEC classifies its business as Biological Products (no Diagnostic Substances). It is incorporated in DE. Its fiscal year ends in December.